AIA Group Ltd Sells 5,369 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AIA Group Ltd decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,848 shares of the biopharmaceutical company’s stock after selling 5,369 shares during the period. AIA Group Ltd’s holdings in Alnylam Pharmaceuticals were worth $5,376,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Allworth Financial LP lifted its stake in Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the last quarter. Nixon Peabody Trust Co. raised its holdings in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares during the last quarter. Nwam LLC boosted its stake in Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 50 shares in the last quarter. Finally, SYM FINANCIAL Corp raised its stake in Alnylam Pharmaceuticals by 6.2% during the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 55 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $268.46 on Monday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company’s 50-day moving average is $259.86 and its 200-day moving average is $260.52. The stock has a market capitalization of $34.92 billion, a PE ratio of -123.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research reports. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Royal Bank of Canada boosted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research note on Friday, March 21st. Bank of America increased their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.